We use cookies for a better user experience. Read our Privacy Policy

I Agree

Venous Diseases Treatment Market

Venous Diseases Treatment Market (Treatment Type: Surgeries and Therapies; and Product: Ablation Devices, Venous Stents, Venous Closure Products, Sclerotherapy Injection, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts, 2022-2031

Venous Diseases Treatment Market Outlook 2031

  • The global venous diseases treatment market was valued at US$ 5.9 Bn in 2021
  • The global market is projected to grow at a CAGR of 6.8% from 2022 to 2031
  • The global venous diseases treatment market is anticipated to reach more than US$ 11.3 Bn by 2031

Analysts’ Viewpoint on Venous Diseases Treatment Market Scenario

Surge in geriatric population, availability of innovative devices for the treatment of venous diseases, occupations that increase the need for venous therapy, and global technical breakthroughs are driving the venous diseases treatment market. Additionally, rise in awareness about venous diseases and their treatments is propelling the global market. Growth in number of treatment centers with private recovery facilities is resulting in treatment access to a larger population. Furthermore, increase in angioplasty operations, rise in burden of vascular illnesses, and surge in demand for minimally invasive procedures are augmenting the global market. Manufacturers should tap into incremental opportunities by focusing on technologically advanced devices for the treatment of venous diseases in order to broaden their revenue streams.

venous diseases treatment market

Venous Diseases Treatment Market Introduction

Venous disorders are diseases that affect the veins in the body. Damaged vein walls obstruct the circulatory system, enabling the blood to collect and flow backward when the muscles relax. This causes an unusually high buildup of pressure in the veins. The accumulation causes stretching and twisting of the veins, increased swelling, valve incompetence, sluggish blood flow, and formation of blood clots. This condition can eventually lead to various disorders known as venous disease. Varicose veins, also known as varicoses or varicosities, are enlarged, twisted veins that can occur anywhere in the body, but are more common in the legs. Varicose veins is one of the most common diseases caused due to damaged vein walls and valves. Rise in prevalence of varicose veins is anticipated to drive the global venous diseases treatment market. According to an article published in the Journal of the American Heart Association, around 23% of adults in the U.S. have varicose veins. Annually, organizations such as the British Association of Sclerotherapies (BAS) launch initiatives to raise awareness and encourage the use of various venous disease treatments. Rise in awareness about deep vein thrombosis treatment, chronic venous occlusions treatment, venous insufficiency treatment, and leg ulcer treatment; and growth in number of product approvals are driving the market. For instance, in November 2020, Vascular Barcelona Devices (VB Devices) received the CE mark approval for Varixio Pod Air, as a Class 1s medical device intended for automated foam preparation for varicose veins sclerotherapy.

Request a sample to get extensive insights into the Venous Diseases Treatment Market

Growth in Preference for Laser Ablation Treatments to Drive Global Market

Laser ablation treatment does not require lengthy hospital stays. It also does not cause discomfort during the recovery process. Adoption of lasers in varicose vein treatment has increased due to the development of novel technologies and advancements in research activities by key players in the market. Doctors are using laser ablation technology to close smaller varicose and spider veins. This treatment involves directing intense bursts of light at the affected veins, causing them to fade or disappear. The usage of laser treatment is increasing in developed countries due to the rise in healthcare costs and growth in preference for non-invasive procedures.

According to a study published in the British Journal of Surgery in May 2022 titled, "Compression following treatment of superficial venous incompetence: systematic review," laser ablation therapy was cost-effective and the preferred initial treatment for symptomatic venous diseases with a diameter of at least 3 mm and evidence of saphenous vein reflux.

Technological Advancements in Vascular Stents and Introduction of New Products to Propel Global Market

Technological advancements in vascular stents, increase in demand for minimally invasive procedures, and rise in geriatric population are some of the factors driving the global market. Companies are expanding their product portfolio to offer the best services for venous diseases. For instance, in March 2022, Cordis, a global cardiovascular technology company, announced that the FDA approved the S.M.A.R.T. RADIANZ Vascular Stent System, a self-expanding stent designed specifically for radial peripheral procedures. The S.M.A.R.T. RADIANZ Vascular Stent System enables accurate and efficient placement of a stent in the iliac and superficial femoral (SFA) arteries.

In December 2021, Royal Philips, a global leader in health technology, announced that it had agreed to acquire Vesper Medical Inc., a medical technology company based in the U.S., which develops minimally invasive peripheral vascular devices. Vesper Medical would add an advanced venous stent portfolio for the treatment of deep venous disease to Philips' portfolio of diagnostic and therapeutic devices.

Request a custom report on Venous Diseases Treatment Market

Increase in Number of Vascular Surgeries Augmenting Global Venous Diseases Treatment Market

In terms of treatment type, the surgeries segment is projected to dominate the global market with 57% share by 2031. Vascular surgery is a surgical subspecialty that treats diseases of the vascular system, which includes arteries, veins, and lymphatic circulation, through medical therapy, minimally invasive catheter procedures, and surgical reconstruction. Vascular diseases are treated using both open surgery and endovascular techniques. Rise in prevalence of varicose veins due to obesity, phlebitis, congenital abnormalities in veins, and blood clots is driving the demand for new treatments. Therefore, companies are offering innovative products, which in turn is propelling the market.

Rise in Cases of Varicose Veins to Boost Global Venous Diseases Treatment Market

Based on disease type, the varicose veins segment dominated the global market with around 24% share in 2021. Rise in prevalence of small and greater saphenous vein, reticular varicose vein, and genital area varicose veins have prompted people to be more aware and educated about varicose vein warning signals and the importance of a prompt response. In July 2019, India Medtronic Private Limited, a subsidiary of Medtronic plc, launched VenaSeal Closure System in India. This led to an improvement in the quality of life of patients living with varicose veins.

Surge in Adoption of Ablation Devices to Create Lucrative Opportunities for Manufacturers

In terms of product type, the ablation devices segment led the global market with around 27% share in 2021. Ablation devices are medical devices used in minimally invasive procedures to remove or excise abnormal body tissues for therapeutic purposes. These systems use the heat generated by radio frequency, energy, extreme cold, or a laser to cause small burns. Rise in adoption of robotic technologies for product application expansion and integration of cutting-edge technologies in ablation devices to improve patient safety and procedural efficiency are expected to drive the segment. Increase in adoption of ablation devices is creating lucrative opportunities for manufacturers in the global venous diseases treatment market.

Increase in Number of Vascular Surgeries Bolstering Hospitals Segment

In terms of end-user, the hospitals segment is projected to dominate the global market with 43% share by 2031. Several hospitals provide treatments for venous diseases. These treatments include endovenous ablation or endovenous laser ablation, radiofrequency ablation, and stripping or surgical ligation. Most surgeons adopt traditional approaches due to high success rates and increase in number of patients preferring traditional approaches. Surge in number of hospitals across the globe along with comparatively higher performance and adoption of minimally invasive surgeries (MISs) in these settings is driving the hospitals segment.

Regional Outlook of Global Venous Diseases Treatment Market

North America dominated the global venous diseases treatment market in 2021. The market in the region is anticipated to grow at a CAGR of 6.8% from 2022 to 2031. It is expected to witness strong growth due to various strategies adopted by key players for market expansion such as product launches, mergers and acquisitions, and collaborations. For instance, in April 2021, Medtronic began an Investigation Device Exemption (IDE) study to determine the efficacy and safety of the Abre venous self-expanding stent device, which is used to treat deep venous disorders.

According to a study titled "Risk assessment for varicose veins among city Police-A cross-sectional study" that was published in Clinical Epidemiology and Global Health in December 2021, in the U.S., around 23% of adults have varicose veins. The prevalence increases to 80% in males and 85% in women when spider telangiectasias and reticular veins are considered. Thus, rise in prevalence of varicose veins among the population of the U.S. is projected to augment the venous diseases treatment market in North America during the forecast period.

Analysis of Key Players in Global Venous Diseases Treatment Market

The global venous diseases treatment market report concludes with the company profiles section, which includes information about key players in the global venous diseases treatment market. Leading players analyzed in the report are Medtronic, AngioDynamics, Alma Lasers, biolitec AG Untere Viaduktgasse, Becton Dickinson and Company, Boston Scientific Corporation, Abbott Laboratories, B. Braun Melsungen Ag, Teleflex Incorporated, Lumenis, and Philips.

Key Developments in Global Venous Diseases Treatment Market

  • In May 2022, THERACLION, a cutting-edge company developing a scalable robotic platform for non-invasive echotherapy, launched SONOVEIN HD. This new system combines the cutting-edge imaging capabilities of SuperSonic Imagine (recently acquired by Hologic) with the first and only extracorporeal therapeutic ultrasound solution.
  • In April 2022, I-VASC, an Italy-based manufacturer of medical devices, closed a EUR 1.8 Mn Series A investment for the introduction of its VELEX product. VELEX is a device that can be used in an operation called Empty Vein Ablation to treat CVI and varicose veins. It obtained its CE Mark in May 2021.
  • In August 2019, Boston Scientific Corporation acquired BTG plc., a London-based company that develops and commercializes products used in minimally invasive procedures targeting cancer and vascular diseases, as well as specialty pharmaceuticals. The addition of the BTG Interventional Medicine portfolio has reinforced Boston Scientific Corporation’s market leadership strategy. It has also enabled the company to offer best-in-class technologies, unparalleled clinical evidence, and a strengthened commercial infrastructure to support physicians treating some of the most challenging diseases.

Each of these players has been profiled in the global venous diseases treatment market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments.

Global Venous Diseases Treatment Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 5.9 Bn

Market Forecast Value in 2031

More than US$ 11.3 Bn

Growth Rate (CAGR)

6.8%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Treatment Type
    • Surgeries
    • Angioplasty or Stenting
    • Vein Ligation and stripping
    • Vena Cava Filter
    • Ambulatory Phlebectomy
    • Others
    • Therapies
    • Sclerotherapy
    • Radiofrequency Ablation Therapy
    • Laser Treatment
  • Disease Type
    • Deep-vein Thrombophlebitis
    • Varicose Veins
    • Superficial Thrombophlebitis
    • Chronic Venous Insufficiency
    • Venous Ulcers
    • Others
  • Product Type
    • Ablation Devices
    • Venous Stents
    • Venous Closure Products
    • Sclerotherapy Injection
    • Others
  • End-user
    • Hospitals
    • Clinics
    • Ambulatory Centers

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Rest of APAC
  • Brazil
  • Mexico
  • Rest of Latin America
  • GCC Countries
  • South Africa
  • Rest of MEA

Companies Profiled

  • Medtronic
  • AngioDynamics
  • Alma Lasers
  • Biolitec AG Untere Viaduktgasse
  • Becton Dickinson and Company
  • Boston Scientific Corporation
  • Abbott Laboratories
  • B. Braun Melsungen Ag
  • Teleflex Incorporated
  • Lumenis
  • Philips

Customization Scope

Available upon request

Pricing

Available upon request

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global venous diseases treatment market in 2021?

The global venous diseases treatment market was valued at US$ 5.9 Bn in 2021.

How big will be the global venous diseases treatment market in 2031?

The global venous diseases treatment market is projected to reach more than US$ 11.3 Bn by 2031.

What will be the CAGR of the global venous diseases treatment market during the forecast period (2022–2031)?

The global venous diseases treatment market is anticipated to grow at a CAGR of 6.8% from 2022 to 2031.

Which are the prominent trends that affect market growth?

New product launches and rise in awareness about the benefits of venous diseases treatment are driving the global market.

What is the market share of the leading segment of the global venous diseases treatment market?

The surgeries segment held over 57% share of the global venous diseases treatment market in 2021.

Which region will account for major share of the global market during the forecast period?

North America is expected to account for major share of the global venous diseases treatment market during the forecast period.

Who are the prominent players in the global venous diseases treatment market?

Medtronic, AngioDynamics, Alma Lasers, Biolitec AG Untere Viaduktgasse, Becton, Dickinson and Company, Boston Scientific Corporation, Abbott Laboratories, B. Braun Melsungen Ag, Teleflex Incorporated, Lumenis, and Philips.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Venous Diseases Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Porter’s Five Force Analysis

5. Key Insights

    5.1. Regulatory Scenario by Region/globally

    5.2. Technological Advancements

    5.3. Pipeline Analysis

    5.4. Key Mergers & Acquisitions

    5.5. Disease Prevalence & Incidence Rate globally with key countries

    5.6. Reimbursement Scenario by Region/globally

6. Global Venous Diseases Treatment Analysis and Forecast, by Treatment Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Treatment, 2017–2031

        6.3.1. Surgeries

            6.3.1.1. Angioplasty or Stenting

            6.3.1.2. Vein Ligation and Stripping

            6.3.1.3. Vena Cava Filter

            6.3.1.4. Ambulatory Phlebectomy

            6.3.1.5. Others

        6.3.2. Therapies

            6.3.2.1. Sclerotherapy

            6.3.2.2. Radiofrequency Ablation Therapy

            6.3.2.3. Laser Treatment

    6.4. Market Attractiveness Analysis, by Treatment

7. Global Venous Diseases Treatment Analysis and Forecast, by Disease Type

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Disease Type, 2017–2031

        7.3.1. Deep-vein Thrombophlebitis

        7.3.2. Varicose Veins

        7.3.3. Superficial Thrombophlebitis

        7.3.4. Chronic Venous Insufficiency

        7.3.5. Venous Ulcers

        7.3.6. Others

    7.4. Market Attractiveness Analysis, by Disease Type

8. Global Venous Diseases Treatment Analysis and Forecast, by Product Type

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Product Type, 2017–2031

        8.3.1. Ablation Devices

        8.3.2. Venous Stents

        8.3.3. Venous Closure Treatments

        8.3.4. Sclerotherapy Injection

        8.3.5. Others

    8.4. Market Attractiveness Analysis, by Product Type

9. Global Venous Diseases Treatment Analysis and Forecast, by End-user

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by End-user, 2017–2031

        9.3.1. Hospitals

        9.3.2. Clinics

        9.3.3. Ambulatory centers

    9.4. Market Attractiveness Analysis, by End-user

10. Global Venous Diseases Treatment Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Market Value Forecast, by Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Market Attractiveness Analysis, by Region

11. North America Venous Diseases Treatment Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Treatment, 2017–2031

        11.2.1. Surgeries

            11.2.1.1. Angioplasty or Stenting

            11.2.1.2. Vein Ligation and Stripping

            11.2.1.3. Vena Cava Filter

            11.2.1.4. Ambulatory Phlebectomy

            11.2.1.5. Others

        11.2.2. Therapies

            11.2.2.1. Sclerotherapy

            11.2.2.2. Radiofrequency Ablation Therapy

            11.2.2.3. Laser Treatment

    11.3. Market Value Forecast, by Disease Type, 2017–2031

        11.3.1. Deep-vein Thrombophlebitis

        11.3.2. Varicose Veins

        11.3.3. Superficial Thrombophlebitis

        11.3.4. Chronic Venous Insufficiency

        11.3.5. Venous Ulcers

        11.3.6. Others

    11.4. Market Value Forecast, by Product Type, 2017–2031

        11.4.1. Ablation Devices

        11.4.2. Venous Stents

        11.4.3. Venous Closure Treatments

        11.4.4. Sclerotherapy Injection

        11.4.5. Others

    11.5. Market Value Forecast, by End-user, 2017–2031

        11.5.1. Hospitals

        11.5.2. Clinics

        11.5.3. Ambulatory centers

    11.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis

        11.7.1. By Treatment

        11.7.2. By Disease Type

        11.7.3. By Product Type

        11.7.4. By End-user

        11.7.5. By Country/Sub-region

12. Europe Venous Diseases Treatment Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Treatment, 2017–2031

        12.2.1. Surgeries

            12.2.1.1. Angioplasty or Stenting

            12.2.1.2. Vein Ligation and Stripping

            12.2.1.3. VeEnd Use Cava Filter

            12.2.1.4. Ambulatory Phlebectomy

            12.2.1.5. Others

        12.2.2. Therapies

            12.2.2.1. Sclerotherapy

            12.2.2.2. Radiofrequency Ablation Therapy

            12.2.2.3. Laser Treatment

    12.3. Market Value Forecast, by Disease Type, 2017–2031

        12.3.1. Deep-vein Thrombophlebitis

        12.3.2. Varicose Veins

        12.3.3. Superficial Thrombophlebitis

        12.3.4. Chronic Venous Insufficiency

        12.3.5. Venous Ulcers

        12.3.6. Others

    12.4. Market Value Forecast, by Product Type, 2017–2031

        12.4.1. Ablation Devices

        12.4.2. Venous Stents

        12.4.3. Venous Closure Treatments

        12.4.4. Sclerotherapy Injection

        12.4.5. Others

    12.5. Market Value Forecast, by End-user, 2017–2031

        12.5.1. Hospitals

        12.5.2. Clinics

        12.5.3. Ambulatory centers

    12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

    12.7. Market Attractiveness Analysis

        12.7.1. By Treatment

        12.7.2. By Disease Type

        12.7.3. By Product Type

        12.7.4. By End-user

        12.7.5. By Country/Sub-region

13. Asia Pacific Venous Diseases Treatment Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Treatment, 2017–2031

        13.2.1. Surgeries

            13.2.1.1. Angioplasty or Stenting

            13.2.1.2. Vein Ligation and Stripping

            13.2.1.3. VeEnd Use Cava Filter

            13.2.1.4. Ambulatory Phlebectomy

            13.2.1.5. Others

        13.2.2. Therapies

            13.2.2.1. Sclerotherapy

            13.2.2.2. Radiofrequency Ablation Therapy

            13.2.2.3. Laser Treatment

    13.3. Market Value Forecast, by Disease Type, 2017–2031

        13.3.1. Deep-vein Thrombophlebitis

        13.3.2. Varicose Veins

        13.3.3. Superficial Thrombophlebitis

        13.3.4. Chronic Venous Insufficiency

        13.3.5. Venous Ulcers

        13.3.6. Others

    13.4. Market Value Forecast, by Product Type, 2017–2031

        13.4.1. Ablation Devices

        13.4.2. Venous Stents

        13.4.3. Venous Closure Treatments

        13.4.4. Sclerotherapy Injection

        13.4.5. Others

    13.5. Market Value Forecast, by End-user, 2017–2031

        13.5.1. Hospitals

        13.5.2. Clinics

        13.5.3. Ambulatory centers

    13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Market Attractiveness Analysis

        13.7.1. By Treatment

        13.7.2. By Disease Type

        13.7.3. By Product Type

        13.7.4. By End-user

        13.7.5. By Country/Sub-region

14. Latin America Venous Diseases Treatment Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Treatment, 2017–2031

        14.2.1. Surgeries

            14.2.1.1. Angioplasty or Stenting

            14.2.1.2. Vein Ligation and Stripping

            14.2.1.3. VeEnd Use Cava Filter

            14.2.1.4. Ambulatory Phlebectomy

            14.2.1.5. Others

        14.2.2. Therapies

            14.2.2.1. Sclerotherapy

            14.2.2.2. Radiofrequency Ablation Therapy

            14.2.2.3. Laser Treatment

    14.3. Market Value Forecast, by Disease Type, 2017–2031

        14.3.1. Deep-vein Thrombophlebitis

        14.3.2. Varicose Veins

        14.3.3. Superficial Thrombophlebitis

        14.3.4. Chronic Venous Insufficiency

        14.3.5. Venous Ulcers

        14.3.6. Others

    14.4. Market Value Forecast, by Product Type, 2017–2031

        14.4.1. Ablation Devices

        14.4.2. Venous Stents

        14.4.3. Venous Closure Treatments

        14.4.4. Sclerotherapy Injection

        14.4.5. Others

    14.5. Market Value Forecast, by End-user, 2017–2031

        14.5.1. Hospitals

        14.5.2. Clinics

        14.5.3. Ambulatory centers

    14.6. Market Value Forecast, by Country/Sub-region, 2017 – 2031

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis

        14.7.1. By Treatment

        14.7.2. By Disease Type

        14.7.3. By Product Type

        14.7.4. By End-user

        14.7.5. By Country/Sub-region

15. Middle East & Africa Venous Diseases Treatment Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Treatment, 2017–2031

        15.2.1. Surgeries

            15.2.1.1. Angioplasty or Stenting

            15.2.1.2. Vein Ligation and Stripping

            15.2.1.3. VeEnd Use Cava Filter

            15.2.1.4. Ambulatory Phlebectomy

            15.2.1.5. Others

        15.2.2. Therapies

            15.2.2.1. Sclerotherapy

            15.2.2.2. Radiofrequency Ablation Therapy

            15.2.2.3. Laser Treatment

    15.3. Market Value Forecast, by Disease Type, 2017–2031

        15.3.1. Deep-vein Thrombophlebitis

        15.3.2. Varicose Veins

        15.3.3. Superficial Thrombophlebitis

        15.3.4. Chronic Venous Insufficiency

        15.3.5. Venous Ulcers

        15.3.6. Others

    15.4. Market Value Forecast, by Product Type, 2017–2031

        15.4.1. Ablation Devices

        15.4.2. Venous Stents

        15.4.3. Venous Closure Treatments

        15.4.4. Sclerotherapy Injection

        15.4.5. Others

    15.5. Market Value Forecast, by End-user, 2017–2031

        15.5.1. Hospitals

        15.5.2. Clinics

        15.5.3. Ambulatory centers

    15.6. Market Value Forecast, by Country/Sub-region, 2017–2031

16. Competitive Landscape

    16.1. Market Player - Competition Matrix (by tier and size of companies)

    16.2. Market Share Analysis, by Company, 2021

    16.3. Company Profiles

        16.3.1. Zimmer Biomet Holdings, Inc.

            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.1.2. Company Financials

            16.3.1.3. Growth Strategies

            16.3.1.4. SWOT Analysis

        16.3.2. Medtronic

            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.2.2. Company Financials

            16.3.2.3. Growth Strategies

            16.3.2.4. SWOT Analysis

        16.3.3. AngioDynamics

            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.3.2. Company Financials

            16.3.3.3. Growth Strategies

            16.3.3.4. SWOT Analysis

        16.3.4. Alma Lasers

            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.4.2. Company Financials

            16.3.4.3. Growth Strategies

            16.3.4.4. SWOT Analysis

        16.3.5. Biolitec AG Untere Viaduktgasse

            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.5.2. Company Financials

            16.3.5.3. Growth Strategies

            16.3.5.4. SWOT Analysis

        16.3.6. Becton, Dickinson and Company

            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.6.2. Company Financials

            16.3.6.3. Growth Strategies

            16.3.6.4. SWOT Analysis

        16.3.7. Boston Scientific Corporation

            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.7.2. Company Financials

            16.3.7.3. Growth Strategies

            16.3.7.4. SWOT Analysis

        16.3.8. Abbott Laboratories

            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.8.2. Company Financials

            16.3.8.3. Growth Strategies

            16.3.8.4. SWOT Analysis

        16.3.9. B. Braun Melsungen AG

            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.9.2. Company Financials

            16.3.9.3. Growth Strategies

            16.3.9.4. SWOT Analysis

        16.3.10. Teleflex Incorporated

            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.10.2. Company Financials

            16.3.10.3. Growth Strategies

            16.3.10.4. SWOT Analysis

        16.3.11. Lumenis

            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.11.2. Company Financials

            16.3.11.3. Growth Strategies

            16.3.11.4. SWOT Analysis

        16.3.12. Philips

            16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.12.2. Company Financials

            16.3.12.3. Growth Strategies

            16.3.12.4. SWOT Analysis

List of Tables

Table 01: Global Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017–2031

Table 02: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017‒2031

Table 03: Global Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017–2031

Table 04: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017‒2031

Table 05: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Region, 2017–2031

Table 06: North America Venous Diseases Treatment Value (US$ Bn) Forecast, by Country, 2017–2031

Table 07: North America Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017–2031

Table 08: North America Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017‒2031

Table 09: North America Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017–2031

Table 10: North America Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017‒2031

Table 11: Europe Venous Diseases Treatment Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 12: Europe Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017–2031

Table 13: Europe Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017‒2031

Table 14: Europe Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017–2031

Table 15: Europe Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017‒2031

Table 16: Asia Pacific Venous Diseases Treatment Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Asia Pacific Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017–2031

Table 18: Asia Pacific Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017‒2031

Table 19: Asia Pacific Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017–2031

Table 20: Asia Pacific Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017‒2031

Table 21: India Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017–2031

Table 22: India Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017‒2031

Table 23: India Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017–2031

Table 24: India Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017‒2031

Table 25: Latin America Venous Diseases Treatment Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 26: Latin America Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017–2031

Table 27: Latin America Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017‒2031

Table 28: Latin America Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017–2031

Table 29: Latin America Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017‒2031

Table 30: Middle East & Africa Venous Diseases Treatment Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 31: Middle East & Africa Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017–2031

Table 32: Middle East & Africa Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017‒2031

Table 33: Middle East & Africa Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017–2031

Table 34: Middle East & Africa Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017‒2031

List of Figures

Figure 01: Global Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031

Figure 02: Global Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022–2031

Figure 03: Global Venous Diseases Treatment Revenue (US$ Bn), by Surgeries, 2017–2031

Figure 04: Global Venous Diseases Treatment Revenue (US$ Bn), by Therapies, 2017–2031

Figure 05: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017–2031

Figure 06: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Product Type, 2017–2031 

Figure 07: Global Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031

Figure 08: Global Venous Diseases Treatment Attractiveness Analysis, by Angioplasty or Stenting, 2022–2031

Figure 09: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Vein Ligation and stripping, 2017–2031

Figure 10: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Vena Cava Filter, 2017–2031

Figure 11: Global Venous Diseases Treatment Value Share Analysis, by Ambulatory Phlebectomy Type, 2021 and 2031

Figure 12: Global Venous Diseases Treatment Attractiveness Analysis, by Others, 2022–2031

Figure 13: Global Venous Diseases Treatment Revenue (US$ Bn), by Sclerotherapy, 2017–2031

Figure 14: Global Venous Diseases Treatment Revenue (US$ Bn), by Laser treatment, 2017–2031

Figure 15: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Radiofrequency ablation therapy, 2017–2031

Figure 16: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Varicose Veins 2017–2031

Figure 17: Global Venous Diseases Treatment Value Share Analysis, by Superficial Thrombophlebitis, 2021 and 2031

Figure 18: Global Venous Diseases Treatment Attractiveness Analysis, by Deep-vein Thrombophlebitis, 2022–2031

Figure 19: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Chronic Venous Insufficiency, 2017–2031

Figure 20: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Venous ulcers, 2017–2031

Figure 21: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Others, 2017–2031

Figure 22: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Ablation Devices, 2017–2031

Figure 23: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Sclerotherapy Injection, 2017–2031

Figure 24: Global Venous Diseases Treatment Attractiveness Analysis, by Venous Closure Treatments, 2022–2031

Figure 25: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Venous stents

Figure 26: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Others, 2017–2031

Figure 27: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Hospitals, 2017–2031

Figure 28: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Clinics, 2017–2031

Figure 29: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Ambulatory centers, 2017–2031

Figure 30: Global Venous Diseases Treatment Value Share Analysis, by Region, 2021 and 2031

Figure 31: Global Venous Diseases Treatment Attractiveness Analysis, by Region, 2022-2031

Figure 32: North America Venous Diseases Treatment Value (US$ Bn) Forecast, 2017–2031

Figure 33: North America Venous Diseases Treatment Value Share Analysis, by Country, 2021 and 2031

Figure 34: North America Venous Diseases Treatment Attractiveness Analysis, by Country, 2022–2031 

Figure 35: North America Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031

Figure 36: North America Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022–2031

Figure 37: North America Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031

Figure 38: North America Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022–2031

Figure 39: North America Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031

Figure 40: North America Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022–2031

Figure 41: North America Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031

Figure 36: North America Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022–2031

Figure 37: Europe Venous Diseases Treatment Value (US$ Bn) Forecast, 2017–2031

Figure 38: Europe Venous Diseases Treatment Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 39: Europe Venous Diseases Treatment Attractiveness Analysis, by Country/Sub-region, 2022–2031 

Figure 40: Europe Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031

Figure 41: Europe Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022–2031

Figure 42: Europe Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031

Figure 43: Europe Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022–2031

Figure 44: Europe Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031

Figure 45: Europe Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022–2031

Figure 46: Europe Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031

Figure 47: Europe Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022–2031

Figure 48: Asia Pacific Venous Diseases Treatment Value (US$ Bn) Forecast, 2017–2031

Figure 49: Asia Pacific Venous Diseases Treatment Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 50: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by Country/Sub-region, 2022–2031 

Figure 51: Asia Pacific Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031

Figure 52: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022–2031

Figure 53: Asia Pacific Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031

Figure 54: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022–2031

Figure 55: Asia Pacific Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031

Figure 56: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022–2031

Figure 57: Asia Pacific Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031

Figure 58: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022–2031

Figure 59: Latin America Venous Diseases Treatment Value (US$ Bn) Forecast, 2017–2031

Figure 60: Latin America Venous Diseases Treatment Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 61: Latin America Venous Diseases Treatment Attractiveness Analysis, by Country/Sub-region, 2022–2031 

Figure 62: Latin America Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031

Figure 63: Latin America Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022–2031

Figure 64: Latin America Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031

Figure 65: Latin America Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022–2031

Figure 66: Latin America Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031

Figure 67: Latin America Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022–2031

Figure 68: Latin America Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031

Figure 69: Latin America Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022–2031

Figure 70: Middle East & Africa Venous Diseases Treatment Value (US$ Bn) Forecast, 2017–2031

Figure 71: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 72: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by Country/Sub-region, 2022–2031 

Figure 73: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031

Figure 74: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022–2031

Figure 75: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031

Figure 76: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022–2031

Figure 77: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031

Figure 78: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022–2031

Figure 79: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031

Figure 80: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022–2031

Figure 81: Company Market Share Analysis, 2021

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved